IARC advised to revisit radiofrequency cancer risk

Posted on Apr 16, 2024

An Advisory Group has recommended that the International Agency for Research on Cancer (IARC) should reassess the cancer risks associated with non-ionizing radiofrequency radiation with high priority. According to the summary issued last week in The Lancet Oncology, the group suggests that the new evaluation should take place in latter half of 5-year period (2025–2029) due to new human cancer and animal cancer evidence to warrant re-evaluation of the classification. Besides radiofrequency fields, several other agents were recommended for revisit, e.g., hair coloring products, acrylamide or paracetamol.
A detailed report of the advisory committee will be published subsequently.